文献速递神经肿瘤

现代内镜经鼻手术作为大泌乳素瘤一线治疗的可行性:多中心研究

Examining the viability of modern endoscopic endonasal surgery as a first-line treatment for macroprolactinomas: a multicentric study on the results and significance of the highest preoperative prolactin level in predicting long-term surgical outcomes.
PubMed 文献 · J Neurosurg · 2025-06-06

多中心回顾76例大泌乳素瘤内镜经鼻手术,全切率56.6%,长期无药缓解率39.3%。术前最高泌乳素<150 µg/L者缓解率80%,≥150 µg/L者仅23.9%,为独立预测因素。

要点

  • 术前最高泌乳素<150 µg/L患者缓解率80%,显著高于≥150 µg/L的23.9%。
  • 全切率56.6%,Knosp分级与斜坡侵犯是独立预测因素。
  • 永久并发症率6.6%,复发率5.9%,学习曲线后期并发症降低。

核心结论

  • 现代内镜经鼻手术在多学科中心是大泌乳素瘤低并发症的选择,但并非普遍根治。
  • 术前最高泌乳素<150 µg/L且不愿长期服药者可考虑早期手术。
  • 仅凭影像学标准不应作为手术决策的唯一因素。

研究设计与样本

  • 多中心回顾性队列,纳入12年间组织学证实的大泌乳素瘤接受内镜经鼻手术的患者76例。
  • 平均年龄42.1±15.6岁,平均肿瘤直径22.7±12.1 mm。
  • 采用多因素回归模型和Kaplan-Meier曲线分析手术结果及决定因素。

主要发现

  • 全切率56.6%,Knosp分级(OR 0.167,CI 0.044-0.633,p=0.008)和斜坡侵犯(OR 0.119,CI 0.019-0.765,p=0.025)是仅有的独立预测因素。
  • 短期缓解52/76例(68.4%),囊性肿瘤缓解率更低(OR 0.004,CI 0.0001-0.0911,p=0.04),计划全切(OR 36.375,CI 1.627-813.128,p=0.023)或实际全切(OR 32.341,CI 1.487-703.558,p=0.027)者更高。
  • 平均随访47.9±33个月,永久并发症率6.6%,3/51例(5.9%)复发,4年无复发生存率在DA依赖患者中显著更低(70% vs 100%,p<0.001)。
  • 末次随访泌乳素与术后第1天水平正相关(相关系数0.403,p<0.001),全切组最终泌乳素正常率显著高于非全切组(76.7 vs 45.2%,p=0.005)。
  • 总体长期无药缓解率39.3%,术前最高泌乳素是唯一独立失败预测因素(OR 0.999,CI 0.996-0.998,p=0.042);亚组分析<150 vs ≥150 µg/L缓解率80% vs 23.9%(p<0.001)。

关键数值与推荐

  • 术前最高泌乳素<150 µg/L者长期缓解率80%,≥150 µg/L者23.9%(p<0.001)。
  • DA抵抗/不耐受患者泌乳素从576降至17 µg/L(p<0.001),51.1%恢复正常,35.6%长期缓解。
  • 学习曲线后半期早期并发症率41% vs 前半期16.2%(p=0.01)。

临床怎么用

  • 对不愿长期服药的大泌乳素瘤患者,若术前最高泌乳素<150 µg/L可考虑早期内镜经鼻手术。
  • 手术决策应综合泌乳素水平、Knosp分级、斜坡侵犯及囊性变等因素,不应仅凭影像学。
  • 术后第1天泌乳素水平可预示末次随访水平,全切与更高泌乳素正常率相关。

局限性

  • 回顾性多中心设计,样本量76例,可能存在选择偏倚。
  • 平均随访47.9个月,长期复发数据有限。
  • 学习曲线效应可能影响并发症率比较。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: As modern endoscopic endonasal surgery (EES) becomes increasingly refined, patients with large prolactinomas may seek alternatives to lifelong dopamine agonist (DA) therapy. This may raise interest in reassessing potential treatment paradigms and surgical outcomes, particularly in patients who have had long-standing symptoms and sought a more definitive solution. The objective of this study was to explore the viability of EES in experienced centers as a reliable alternative to managing macroprolactinomas. METHODS: A multicentric cohort of patients with histologically proven macroprolactinoma treated with EES over 12 years was retrospectively reviewed. Early surgical results and the determinant factors of outcome were analyzed using a multivariate regression model and Kaplan-Meier curves. RESULTS: A total of 76 patients with a mean ± SD age of 42.1 ± 15.6 years and tumor diameter of 22.7 ± 12.1 mm was included. Gross-total resection (GTR) was achieved in 56.6%, with Knosp grade (OR 0.167, CI 0.044-0.633, p = 0.008) and clival invasion (OR 0.119, CI 0.019-0.765, p = 0.025) being the only independent predictors. Short-term remission (52/76 patients [68.4%]) was less frequent in patients with cystic tumors (OR 0.004, CI 0.0001-0.0911, p = 0.04) and was higher in those with intended (OR 36.375, CI 1.627-813.128, p = 0.023) or achieved (OR 32.341, CI 1.487-703.558, p = 0.027) GTR in multivariate analysis. The second half of the learning curve showed early complication rates of 41% versus 16.2% in the first half (p = 0.01). During a mean 47.9 ± 33 months of follow-up, the permanent complication rate was 6.6% and 3/51 patients (5.9%) had recurrence. Overall 4-year recurrence-free survival was significantly lower in DA-dependent patients (70% vs 100%, p < 0.001). Last follow-up prolactin levels were positively correlated with postoperative day 1 levels (correlation coefficient 0.403, p < 0.001), with final normoprolactinemia rates significantly higher in the GTR group than in the non-GTR group (76.7 vs 45.2%, p = 0.005). DA-resistant/intolerant patients achieved significant prolactin levels reduction (576 to 17 µg/L, p < 0.001), with normal prolactin level in 51.1% of patients and long-term remission in 35.6%. The overall long-term DA-free remission rate was 39.3%, with the highest preoperative prolactin level (OR 0.999, CI 0.996-0.998, p = 0.042) being the only independent predictor of failure. Subgroup analysis showed remission rates of 80% versus 23.9% in patients with the highest preoperative prolactin levels < 150 versus ≥ 150 µg/L, respectively (p < 0.001). CONCLUSIONS: The authors found that modern EES in multidisciplinary centers was a low-morbid option for patients with macroprolactinoma. Remission rates were consistent with those of recent studies with variably sized prolactinomas, and recurrence rates were low. Although not universally definitive for macroprolactinomas, early EES can be offered for patients with the highest preoperative prolactin levels below 150 µg/L who are unwilling to receive long-term medication. Radiological criteria alone should not be the sole factor in surgical decision-making.

来源:J Neurosurg,查看原文。版权归原作者所有。

引用

  1. Khaleghi M, Huntoon KM, Zandbergen IM, et al. Examining the viability of modern endoscopic endonasal surgery as a first-line treatment for macroprolactinomas: a multicentric study on the results and significance of the highest preoperative prolactin level in predicting long-term surgical outcomes. J Neurosurg. 2025. PMID: 40479816. doi:10.3171/2025.1.JNS241645

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。